Sponsor Name: Eli Lilly and Company
Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate
the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have
Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)
Protocol Number: J1I-MC-GZQD
Regulatory Agency Identifier Numbers: IND: 162070
Brief Summary: The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.